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Human Papillomavirus (HPV) has a significant impact in 
male’s health, as cause of clinical manifestations ranging 
from genital warts to several cancers of the anogenital and 
aero-digestive tract. HPV types which most frequently affect 
men are 6,11,16 and 18, included in the HPV quadrivalent 
vaccine, recently approved for use in males by Food and 
Drug Administration (FDA) and European Medicines Agency 
(EMA). Although several data about the safety and efficacy 
of quadrivalent vaccine are available, the implementation of 
proper immunization plans dedicate to male’s population can-
not ignore the knowledge of the characteristics of the disease 
in men, which in some aspects should be clarify, in particular 
clearance of type-specific HPV infections and transmission 
dynamics. Purpose of this review is to summarise the main 
information about the burden and the natural history of the 
HPV related disease in males.
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Summary
Introduction
The human papillomavirus also known as HPV is a 
ubiquitous virus causative agent of proliferative lesions 
of the skin and mucous membranes and represents one 
of the most frequent sexually transmitted infection in 
both men and women [1].
The demonstration of a causal link between some high-
risk HPV sub-types and cervical cancer has focused the 
attention of scientific community on HPV infections in 
female leading to the development of highly effective 
prophylactic HPV vaccines [2-4]. 
The earlier studies on HPV in males were conducted on 
Man having sex with Man (MSM) and HIV+ to deter-
mine cancer risk associated to HPV infections [5,  6], 
subsequently the interest has shifted on HPV infections 
in heterosexual males, especially to clarify their role in 
the transmission of infection to woman [7, 8].
Several studies demonstrated the significant impact of 
HPV in males as cause of important disease ranging 
from genital warts to several cancers of anogenital and 
aerodigestive tracts [9].
The International Agency for Research on Cancer 
(IARC) in 2009 revised the carcinogenic role of HPV 
in human pathology reporting an association with penile 
and anal cancers and with cancers of oral cavity, oro-
pharynx, larynx and esophagus [10].
Based on data derived from several studies of vaccine 
efficacy conducted on males, in 2009 Food and Drug 
Administration (FDA) licensed the use of the HPV 
quadrivalent vaccine for the prevention of genital warts 
in males aged 9-26 years and in 2010 the use of quad-
rivalent vaccine was also extended for the prevention 
of anal cancer and associated precancerous lesions for 
males and females aged 9-26 years [11, 12].
The use of quadrivalent vaccine against HPV has been 
extended for the prevention of genital warts in males 9 
to 26 years also by the European Commission, which 
endorsed the opinion of the Committee for Medicine 
Products for Human Use (CHMP) European Medicines 
Agency (EMA) [13].
Despite the availability of the HPV vaccine for use in 
males, only few countries in the world have developed 
vaccine programs dedicated to this susceptible popula-
tion, due to the lack of knowledge of some aspects of the 
natural history of the disease in men, in particular, the 
duration and the clearance of type-specific HPV infec-
tions together with transmission dynamics.
The explanation of such data is essentials for the imple-
mentation of extended screening programs and for the 
definition of appropriate vaccination plans directed to 
male’s population.
The aim of this review is to summarize the latest knowl-
edge about HPV epidemiology in males, which can pro-
vide a starting point for the implementation of cost ef-
fective preventive strategies.
Human papillomavirus
HPV, currently classified within papillomavirus family, 
is a naked icosahedral virus with a diameter varying be-
tween 45 and 55 nm containing a double-stranded circu-
lar DNA genome of 8000 bp [14].
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HPV genome includes 8 “early genes” E1-E8, which 
encodes for proteins facilitating viral replication and 
stimulating cell proliferations, 2 “ late genes” L1 and 
L2, encoding for structural proteins and an upstream 
regulatory region (URR) or long control region (LCR) 
including sequences for the control of transcription and 
the origin site for DNA replication.
Based on DNA sequence homology of the E6, E7 and 
L1 open reading frames (ORFs) more than 100 HPV 
types were identified, of which approximately 40 types 
are known to infect the genital epithelia. 
Genital HPV types depending on their oncogenic pro-
pensity were classified at “low” risk, which usually give 
rise to a productive infection in permissive cells remain-
ing episomial, and at “high/intermediate” risk, which in 
non-permissive cells integrates into genome inducing 
transformation.
A regulatory pathway involving E2, E6 and E7 genes 
has been shown to be at the origin of carcinogenesis.
In particular, the integration of HPV carcinogenetic type 
into cellular genome, lead to the inactivation of E2 viral 
protein which usually inhibits E6 and E7 genes expres-
sion [15-17].
E6 and E7 early genes play a key role in carcinogenesis 
acting as oncogenes by binding and deactivating p53 
and p150rb tumor suppressor proteins respectively [18].
A set of about 40 types were frequently associated with 
sexually transmitted infections and with pathogenesis of 
the ano-genital tract cancer, among them HPV types 6, 
11, 40, 42, 43, 44, 53, 54, 61, 68, 70, 72, 81, frequently 
associated to genital warts and low-grade squamous in-
traepithelial cervix lesions, are classified as low-risk, 
conversely, HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, 68, 73 and 82 are referred to as high-risk 
and are related with malignant lesions of cervix, vulva, 
penis and anus [19].
Natural history of HPV infection in males
Little is known about HPV infection in men especially 
in terms of duration and transmission dynamics although 
such information are essential for the adoption of ap-
propriate preventive interventions and are the subject of 
several investigations.
The first studies about HPV disease in males focused on 
small groups of men, especially homosexuals and HIV 
positive who were not representative of the general pop-
ulation. Therefore, data derived from such works have 
been of little use to the understanding of the natural his-
tory of the disease in male population.
Recently, the focus of research has shifted to heterosexu-
al men, being heterosexual transmission the major route 
of spread of infection and the males seems to exert a key 
role acting as an asymptomatic reservoir of HPV [20].
Data derived from a cross-sectional study of HPV infec-
tion conducted in 463 men from 2003 to 2006 reported 
an overall prevalence of HPV infection of 65.4% with 
penile shaft, gland penis/coronal sulcus and scrotum 
sites presenting the highest positivity for HPV DNA 
among asymptomatic heterosexual men [21].
Results from a cohort study of HPV infections conduct-
ed on 240 heterosexually active male university student 
ages 18-20 years in United States showed a prevalence 
of any genital HPV type of 25.8% and a cumulative inci-
dence of new infection of any genital HPV type of 62.4% 
(95% confidence interval [CI], 52.6%-72.2%). Cumula-
tive incidence of high-risk HPV types was 47.9% (95% 
[CI], 38.6%–58.0%) [22].
The large continuous prospective HPV in Men study 
(HIM) whose aim was to study natural history of HPV 
disease in males aged 18-70 years in three countries (Bra-
zil, Mexico and United States) reported an incidence of 
new genital HPV infection of 38,4/1000 months person 
for any HPV type. Concerning the incidence of HPV on-
cogenic type was estimated to be 22.2 / 1000 (95% [CI], 
19.8%-24.9%) month’s person, with types 16,51,52 and 
59 showing the highest incidences.
The median time to clearance of HPV infection was 7.52 
months for any HPV type, with the longest clearance 
observed in males aged 18-30 years, and 12.19 months 
for HPV oncogenic type 16, whose clearance was not 
age dependent. Moreover, clearance of oncogenic HPV 
types in males appeared inversely related to the number 
of lifetime female partners and has shown to be more 
rapid with increasing age. In this study also emerged a 
decreased clearance of oncogenic HPV types infection 
in men in Brazil and Mexico compared with the United 
States [23].
A recent study highlighted that prevalence of HPV in 
men varies according to different geographical areas 
and by race with the lowest prevalence among Asian/
Pacific islanders (42.2%) compared to Blacks (66.2%) 
and Whites (71.5%). Further studies will be necessary to 
clarify the low prevalence of HPV in Asian populations, 
it has been suggested that sexual behavior and race-spe-
cific differences such as variations in the genes involved 
in immunomodulation can explain these data [24].
Giuliano et al. examined data about the incidence and 
clearance of HPV infection emerged from two studies 
conducted on women of 18-35 years and males 18-44 
years, respectively. The comparison revealed similar pe-
riod prevalences for any HPV infection (52.8% in men 
and 53.8% in women), and similar HPV incidence rates 
(29.4 per 1000 person-months in both men and women). 
Moreover males also showed a similar probability of 
acquiring infection with oncogenic and non-oncogenic 
types against a significantly higher probability of ac-
quiring oncogenic types in females. The clearance of 
the infection was similar in males for all HPV types, 
while in females the clearance of oncogenic types was 
slowe  [25].
About the transmission dynamics several studies of het-
erosexual partners have been performed to understand 
the role that partners may have in the spread of HPV 
infection.
Burchell et al. demonstrated a 64% concordance for at 
least one HPV type among partners of recently formed 
heterosexual couples [26].
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The same authors in a more recent study have examined 
179 newly formed heterosexual couples experiencing a 
transmission male-to-female rate of 3.5 per 100 person-
months (95% [CI], 2.7-4.5) versus a female-to-male rate 
of 4.0 per 100 person-months (95% [CI], 3.0-5.5). More-
over, no change in the transmission rate across HPV 
genotypes and no changes in the rate in dependence on 
the lifetime number of partners reported by the initially 
uninfected partner were observed [27].
Nytray et al in examining 88 heterosexual couples dem-
onstrated a 59% type-specific positive concordance and 
that the latter was associated with an increasing difference 
in partners’ lifetime number of sex partners and inversely 
related to the increasing difference in age [28].
Several studies conducted on females partners of males 
with HPV lesions highlighted in these an increased risk 
of developing cervical carcinoma on the contrary, studies 
conducted on male partners of women suffering of cervi-
cal intraepithelial neoplasia (CIN I) showed HPV lesions 
detectable only in 50% of the cases, according to the hy-
pothesis of a lesser receptivity to or a more effective clear-
ance of HPV infection in men than in women [29, 30].
Martin-Ezquerra et al reported an overall 41% of HPV 
diagnosed infections among male partners of women 
with CIN II and III [31].
Recent evidence suggested that HPV infection in males, 
also with high-risk serotypes, is not always associated 
with the development of cervical lesions in female’s 
sexual partners [30].
Centers for Disease Control and Prevention (CDCs) 
recommend the screening of male’s sexual partners of 
women suffering from HPV infection in order to high-
light and possibly treat any exophytic lesion [32] even 
if the treatment does not appear related to a reduction 
in the risks of development of precancerous cervical le-
sions.
Although sexual contact represents the major route of 
transmission, HPV can be transferred on genital organs 
indirectly due to its ubiquity and environmental resistance.
In particular, skin contact would be the main route of 
indirect transmission (90% of cases); also transfer of in-
fection by inanimate objects was demonstrated between 
sexual partners [33].
Clinical manifestation associated  
with HPV infections in males
HPV replicates in differentiated squamous epithelial 
cells of the skin and mucous membranes causing prolif-
erative lesions ranging from asymptomatic infections to 
malignant lesions.
The healthy carrier state is the more common condi-
tions for males so that several studies have focused on 
their role in the transmission of oncogenic HPV types to 
women [20].
The most frequent HPV clinical manifestations in males 
are condylomata acuminata (genital warts), wart-like le-
sions of oropharyngeal tract and less commonly cancers 
of the penis, anus and oral cavity cancer.
Genital warts
Genital warts, one of the most frequently diagnosed 
sexually transmitted infections, are benign genital le-
sions with symptoms such as local pain and bleeding 
without serious consequence, but frequently associ-
ated with psychosocial distress and significant medical 
costs [34-36].
HPV lesions are very infectious with a transmission rate 
of > 60% within sexual partnerships from an infected 
to a susceptible sexual partner. Most of genital warts 
develop 2-3 months after infection, with an incubation 
period ranging from 2-8 months [37].
Several studies reported a spontaneous regression rate 
up to 40% even if in some cases genital warts may re-
cur [38-40].
The most common genotypes detected from condylo-
mata acuminata are non-oncogenic 6 and 11 HPV types 
with a frequency of 70–100% of exophytic genital wart 
tissue containing one of these types, while one-third of 
lesions have multiple HPV types including co-infection 
with oncogenic types [41, 42].
It has been estimated that about 1% of sexually active 
men in the United States have genital warts at any one 
time with an incidence peak of 5.01 per 1000 person-
years in the age group 25-29 years. [34, 43] 
In Europe, data from two recent studies reported an in-
cidence of genital warts in males ranging from 147.95 
per 100,000 men-years in Germany (95% [CI], 144.48 
to 151.48) to 168 per 100,000 men years in United King-
dom [44, 45].
Based on these studies Hartwig et al. estimated an ex-
pected number of new genital warts cases ranging from 
335.301 to 380.961 [46]. 
Recent data about the trend in genital warts infections 
in UK based on Genitourinary Medicine (GUM) clinics 
attendances during the period 2006-2010 show a marked 
increase of diagnosed cases from 148.5 per 100,000 to 
160.5 per 100,000 [47].
A study conducted to determine the incidence of genital 
warts before and after the introduction in female popula-
tion of the quadrivalent human papillomavirus vaccine 
in Sweden, reported 1137 cases/100,000 among males 
aged > 24 years during 2006-2007; a further increase in 
incidence of genital warts among males together with 
a decrease in females was observed between 2008 and 
2010 (Tab. I) [48].
The Italian Sentinel Surveillance of sexually transmitted 
infections (STIs) reported that between 1991 and 2007, 
the genital warts were the most common diagnosed sex-
ually transmitted diseases with 73% of cases in males 
and a prevalence peak in the age group 14-25 years [49].
It has been assessed that in Italy, 89% of genital warts 
were diagnosed from heterosexual patients while 
10,1% were from homosexual/bisexual. Among males, 
an association between number of sex partners (>  2) 
and concomitant STDs was demonstrated in 50% and 
17.1% of genital warts cases, respectively. Moreo-
ver 6.9% of males presenting genital warts were also 
HIV+ [49].
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Recurrent respiratory papillomatosis
Recurrent Respiratory Papillomatosis (RRP) is a rare 
and highly morbid pathological condition caused by 
HPV types 6 and 11 and characterized by the recurrent 
appearance of warts like lesions in the respiratory tract, 
particularly at the larynx and vocal cords [50].
The disease is particularly severe among children who 
require frequent surgeries to remove recurrent obstruc-
tive lesions.
RRP is most commonly diagnosed among children with-
out distinction between genders while it is rarely diag-
nosed in adults in which affects more males between 
ages 20 and 30 years [51].
Data from a national survey of practicing otorynolaryn-
gologists in the United States in 1993-1994 provided an 
incidence of 4.3 per 100,000 in children and of 1.8 per 
100,000 in adults [51].
Data derived from two European studies reported an 
RRP incidence of 0.35-0.38 per 100,000 person-years 
with a sex ratio for juvenile onset of 1:1; a different dis-
tribution of the disease were observed in adults, with a 
higher frequency in males (Tab. I) [46].
About transmission dynamics several studies dem-
onstrated a vertical HPV transmission from mother to 
child during birth, while RRP cases among adults may 
develop as the results of oro-genital sexually transmitted 
HPV infections [52].
Anal cancer
The incidence of anal cancer is increasing worldwide 
in men and women with 99.000 new cases estimated in 
2002, 40% of cases in men and 60% in women [53].
HPV infections are well known as the main cause of 
squamous cell carcinoma of the anus (anal SCC) and has 
been identified in more than 80% of anal canal cancer 
cases with HPV 16 and 18 oncogenic types responsible 
of 87% and 9% of intraepithelial lesions, respectively. 
HPV DNA detection in anal intraepithelial neoplasia 
(AIN) correlates with their cytological and histological 
severity: 75% in AIN 1 (mild), 86% in AIN 2 (moder-
ate), and 94% in AIN 3 (severe) [54].
In Europe anal cancer cases among men generally first 
occurs in the age group 30-35 years, with an estimated 
value of 1821 new yearly-diagnosed cases due to HPV 
of which 1699 were attributable to HPV 16 and 18 types 
(Tab. II) [46]. 
A twofold increase in the anal cancer incidence was re-
ported in United States after the advent of the HIV pe-
riod during which was reached an estimated value of 35 
per 100 000 among MSM (Tab. II) [5, 20]. 
Relative risk of developing anal cancer was highest 
among HIV infected man and among man who were 
HIV infected through homosexual contact with reported 
values of 37.9% (95% CI = 33.0-43.4) and 59.5% (95% 
CI = 51.5-68.4) respectively; consequently the majority 
of studies on prevalence of anal HPV infection has fo-
cused on these susceptible populations [55]. 
In a study about the incidence and the risk factors of 
anal cancer between 1992 and 2004 based on the French 
Hospital Database on HIV, Piketty et al reported that the 
majority of cases occurred among males (94%) of which 
75% was homosexual. Moreover the incidence of anal 
cancers was higher in the years 1999-2004 (40/100,000; 
95% [CI], 32 to 47) after the introduction of the high-
ly effective antiretroviral Highly Active Antiretrovi-
ral Therapy (HAART) therapy [56]. 
Data derived from a study conducted in United States on 
4.506 HIV infected males showed a continuous increase 
Tab. I. Studies reporting incidence of hpv-related non-malignant diseases in different populations.
Country, year, Author Disease Population Design
Incidence
(95%CI)
United States, 2000
Insinga, 2003[34]
genital Warts
privately insured 
populations
retrospective
(medical records)
5.01/ 1000
man-years 
germany, 2006
Kraut 2010 [44]
genital Warts
general population
(10-79 years)
retrospective cohort
147.95/100,000
man-years
(144.48-151.48)
United Kingdom, 2009
desai, 2011[45]
genital Warts
general practice + 
gUm clinic attendees
retrospective cohort
166/100,000
man-years 
United Kingdom, 2006-2011
hpA, 2012[47]
genital Warts gUm clinic attendees Survey
148.5/100,000
man-years (2006)
160.5/100,000
man-years (2011)
Sweden, 2006-2007
Leval, 2012 [48]
genital Warts
general populations
(10-44 years)
retrospective
(medical records)
1137/100,000
man-years 
United States, 1993-1994
derkay, 1995[51]
recurrent 
respiratory 
papillomatosis
Children and
Adults both sexes
Survey
4.3/100,000
children-years
1.8/100,000
 adults-years
denmark, 1965-1984
denmark, 1974-1999
hartwig, 2012[46]
recurrent 
respiratory 
papillomatosis
Children and
Adults both sexes
review
0,35-0,38/100,000
person-years
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in cancer rates reaching a value of 128/100.000 (95% 
[CI], 16 to 1042.2) in 2006-2008. In particular, cancer 
risk was higher among the patients who had acquired 
infection by more than 15 years and HAART therapy 
length did not seem to confer protection against anal 
cancer (Tab. II) [57]. 
This observation was confirmed in a recent work con-
ducted to evaluate the trends in the incidence of anal 
cancers between HIV infected patients receiving long-
term combined antiretroviral treatment (cART) between 
1992 and 2008. In this study, standardized incidence 
ratios (SIRs) of anal cancer in HIV-infected patients 
proved to be high among MSM 109.8 (95% [CI], 84.6 
to 140.3) and others HIV infected males 49.2 (95% [CI], 
33.2 to 70.3) and no differences were observed between 
pre and post cART periods, consequently combined an-
tiretroviral treatment appears to have no preventive ef-
fect on anal cancer [58].
Although little is known about immunomodulation 
mechanisms versus HPV infections, it is reasonable that 
immunosuppressive state could favor HPV infection at 
the early stage of transformation of precancerous le-
sions while the subsequent progression of the persistent 
lesions to invasive cancer could be induced by genetic 
mutations accumulated over time. The increased life ex-
pectancy of HIV infected patients favored by combined 
antiretroviral treatment may extend time to progression 
of lesions to cancer.
Specimens from anal cancers in MSM are almost always 
HPV DNA positive; suggesting that epithelial site of in-
fection and frequency of exposure are factors that may 
affect the risk of infection [59].
 It was postulated that the increased risk of developing 
anal cancer in MSM could be attributed to the presence 
of a HPV, susceptible transformation zone similar to that 
of the cervix [60].
Recent studies focused on HPV infections in traditional-
ly non-high-risk groups, i.e. heterosexual men and HIV 
negative subjects, reported that anal and perianal HPV 
infections are very common.
Nyitray et al in a cross-sectional study conducted in 
United States to assess the prevalence of and risk factors 
for anal HPV infection in asymptomatic heterosexual 
men stated an overall prevalence of anal HPV infection 
of 24.8% in 222 men among which 33.3% had an onco-
genic high-risk HPV type [61].
Data derived from the recent HIM study conducted on 
men residing in Brazil, Mexico, and the United States 
reported that the prevalence of anal canal HPV was 
12,2% and 47,2% in both HIV negative heterosexual 
and homosexual men respectively [62].
The lifetime number of sexual partners is the main risk 
factor associated with anal HPV infections as emerged 
in both the cited studies. 
Other reported risk factors for anal cancer common in 
men and women are history of genital warts, anal inter-
course, and cigarette smoking [63].
Of particular interest are the findings from a study about 
the persistence and clearance of anal infection with HPV 
oncogenic types among men, showing a 6 month anal 
persistence of HPV 16 in 5.1% of MSM while no persis-
tence was observed in heterosexual men [64].
The more rapid clearance of infection may partially 
explain the lower incidence of anal cancer than that of 
cervical, whereas the persistence of lesions could lead 
to neoplastic transformation and to the development of 
invasive cancer.
Penile cancer
Penile cancer is a rare disease accounts for less than 
0,5% of cancer cases among males worldwide with an 
estimated incidence of less than 1/100.000 in developed 
countries [65].
The age-adjusted incidence rates for penile cancer in 
the United States during 2004-2008 was about 1.3 per 
100.000 among Hispanic men compared to 0.7 per 
100.000 in non-Hispanic men; [66] these data confirm 
the trend observed in Latin American countries (Brazil, 
Peru, Colombia), where penile cancer incidence is high-
er and amounts to 1.5-3.7 per 100,000 inhabitants. Inci-
dence of penile cancer is highest in developing countries 
with a rate of 2,8/100.000 in Uganda and of 1,7/100.000 
in Thailand and India (Tab. II) [10]. 
On the contrary, incidence is particularly low in the Jew-
ish population that commonly practice neonatal circum-
cision with an estimated rate of 0,04/100.000 [10,66].
In Europe penile cancer tends to increase by age, reach-
ing a peak in the seventh decade of life. Each year were 
diagnosed 3178 penile cancer cases (95% [CI], 2,623 to 
3,751), the half of which, considering an overall HPV 
prevalence of 46,7%, could be attributed to HPV [46].
Data from the Italian Association of Cancer Registries 
reported a standardized rate of penile cancer of 1 per 
100,000 during the year 2007 (Tab. II) [67]. 
Detection of HPV DNA in penile cancer has ranged 
from 40% to 50%, with HPV 16, 18 and 33 identified as 
the most common types [68].
HPV DNA positivity varies by histological subtype and is 
higher in basaloid and warty types with an estimated fre-
quency of 80%-100%, while is low (30-60%) in squamous 
cell carcinoma, which is the most common type of penile 
cancer accounting for 90% to 95% of cases [69, 70].
Interestingly, incidence of penile cancer remains much 
lower than that of the cervix; a possible explanation 
could be the lower susceptibility of the penile tissue to 
HPV oncogenic types [59].
Among the risk factors associated with penile cancer 
may be cited: history of anogenital warts, number of 
multiple female sexual partners, lack of neonatal cir-
cumcision, phimosis, early age of first intercourse, ciga-
rette smoking [71, 72].
Head and neck cancers
HPV related head and neck cancers include squamous 
cell carcinoma of the oral cavity, oropharynx, hypophar-
ynx, and larynx.
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It was estimated that in 2002 405.000 new cases of head 
and neck cancers occurred worldwide, with a high fre-
quency in South and Central Asia [73].
The expected annual HPV associated oropharyngeal 
cancer cases based on United States cancer registry data 
amounted to 9.356 among males [74].
The estimated number of new HPV related head and 
neck cancers cases among men in Europe accounted to 
14,098 (95% [CI], 11,455 to 17,077), including cancers 
of the oral cavity, oropharyngeal cancers and laryngeal 
cancers [46]. 
The Italian Association of Cancer Registries reported an 
age-adjusted incidence rates in males of 2,5 per 100,000, 
1,3 per 100,000 and 2,6 per 100,000 for oropharyngeal, 
hypo-pharyngeal and oral cancers from all causes re-
spectively, in 2007 (Tab. II) [67]. 
Although the main risk factors for head and neck squa-
mous cell carcinomas (HNSCCs) are represented by 
Tab. II. Studies reporting incidence, prevalence and expected number of cases of hpv related cancers in different populations.
Country, year, 
Author
Cancer 
type
Population
Incidence
(95%CI)
Prevalence 
of HPV by 
cancer site 
(%) (95%CI)
Expected 
number of 
new cases, 
irrespective 
of HPV status 
(bounds)
Expected 
number of 
new cases 
attributable to 
HPV (bounds)
World
WhO, 2012 [53]
Anal 
Worldwide 
populations
(both sexes)
Nd Nd 99,000 /year Nd
germany 
varnai, 2006 [54]
Anal 
Samples from 
87 patients with 
diagnosed AIN
(both sexes)
Nd 80.9 Nd Nd
europe
hartwig, 2012[46]
Anal 
european
populations 
(males)
Nd
84.2
(81.5-86.9)
Nd
1,821/year
(1,403-2,277)
United States
Chin-hong, 2004 [5]
Anal mSm
35/100,000
man-years
Nd Nd Nd
France
piketty, 2008 [56]
Anal 
hIv infected 
patients
(both sexes)
40/100,000
person-years
(32-47)
Nd Nd Nd
United States
Crum-Cianflone, 
2010 [57]
Anal 
hIv infected 
patients
(both sexes)
128/100.000
man-years
(16-1042.2)
Nd Nd Nd
United States
CdC, 2012 [66]
penile 
general 
populations
0.7-1.3/100.000 Nd Nd Nd
Latin American 
countries
IArC, 2007 [10]
penile 
general 
populations
1.5-3.7/100,000 Nd Nd Nd
Uganda
IArC, 2007[10]
penile 
general 
populations
2.8/100,000 Nd Nd Nd
europe
hartwig, 2012[46]
penile 
general 
populations
Nd 46.7
3178/year
(2,623-3,751)
1484/year
(1,102-1,925)
Italy
AIrTUm, 2007 [67]
penile 
general 
populations
1/100,000 Nd Nd Nd
World
parkin, 2002 [73]
head and 
Neck
general 
populations
(both sexes)
Nd Nd 405,000/year Nd
United States
CdC, 2012 [74]
head and 
Neck
general 
populations
males
Nd Nd 9,356/year Nd
europe
hartwig, 2012 [46]
Oral cavity, 
oropharynx 
larynx
general 
populations
males
Nd Nd Nd
14,098/year
(11,455-17,077)
Italy
AIrTUm, 2007 [67]
oropharynx
hypo-
pharynx
oral cavity
general 
populations
males
2.5-1.3-
2.6/100,000
man-years
Nd Nd Nd
World
Kreimer, 2005 [77]
head and 
Neck
5,046 hNSCC 
cancer specimens
(both sexes)
Nd
25,9
(24.7-27.2)
Nd Nd
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tobacco smoking and alcohol consumption the role of 
HPV is important with up to 60% of biopsies positive for 
HPV DNA [75, 76]. 
Data from a systematic review reported an overall 
HPV DNA prevalence of 25,9% (95% [CI], 24.7-27.2) 
among HNSCCs biopsies collected worldwide, with a 
prevalence peak of 35,6% (95% [CI], 32.6-38.7) in oro-
pharyngeal cancer. HPV 16 was identified in the larger 
majority of HPV-positive oropharyngeal SCCs (86.7%, 
95% [CI], 82.6-90.1) and remains the predominant type 
(Tab. II). [77]
D’Souza G. et al. in a case-control study demonstrated 
a significant association between oropharyngeal cancer 
and oral HPV type 16 infections (odds ratio 14.6%; 95% 
[CI], 6.3 to 36.6) both revealing a relationship between 
oral HPV infection and oral intercourse [78].
HPV and male fertility
Some studies have shown how HPV DNA is present in 
sperm cells both in infected and healthy individuals and 
although no direct relationship between HPV infection 
and male fertility has been demonstrated, preliminary 
data indicate that the presence of HPV can affect sperm 
function.
In particular it has been shown that HPV can bind to 
sperm cells surface reducing their motility revealing a 
possible cause of infertility [79].
A study by Foresta et al conducted to evaluate a possible 
association between HPV sperm infection and reduction 
of sperm cell function in infertile patients showed a sig-
nificantly higher percentage of HPV infection on sperm 
of infertile patients [80].
Recent evidence on animal models suggested that HPV 
infected spermatozoa are able to penetrate the oocyte 
transferring the viral DNA within it acting as vectors for 
HPV transfer. 
HPV genome within the oocyte is activated and tran-
scribed and may interfere with embryo development re-
ducing its ability to survive [81].
A prospective study performed on 199 infertile couples 
undergoing assisted reproductive technologies (ARTs) 
showed a highly statistically significant correlation be-
tween pregnancy loss rate (66,7%) and positive HPV 
DNA testing in the male partner. In the light of these 
findings HPV could be a causal factor both of infertility 
in man and of ARTs failure [82].
Vaccination
Currently, two HPV vaccines are available: a bivalent 
vaccine (Cervarix) targeted the oncogenic HPV16 and 
HPV18 types, recommended for the prevention of cer-
vical cancer in women aged 10-25 years, and a quad-
rivalent vaccine (Gardasil) directed against the HPV 
types 6,11,16 and 18, recommended for the prevention 
of precancerous lesions of cervix, vulva and vagina and 
of genital warts in women aged 10-45 years and in men 
aged 9-15 years [83, 84].
Many data are currently available regarding the efficacy 
of quadrivalent vaccine, the only HPV vaccine approved 
for use in men, in the prevention of genital and anal le-
sions among males population.
Giuliano et al. in a double-blind, randomized, placebo-
controlled trial evaluated the efficacy of the quadriva-
lent vaccine (Gardasil) in young men (4065 subjects) 
between 16 and 26 years of age. The results at a median 
follow-up of 2.9 years showed an effectiveness of 84% 
in preventing external genital lesions caused by all HPV 
types (warts, penile intraepithelial neoplasia, perianal 
and perineal neoplasia) caused by all HPV types. Vac-
cine efficacy was 90% against genital lesions related to 
the types 6,11,16 and 18 included in the vaccine [85].
Palefsky et al. in a double-blind trial conducted on 602 
healthy homosexual men aged 16-26 years have evalu-
ated the efficacy of the quadrivalent vaccine for pre-
vention of anal intraepithelial neoplasia. Data from this 
study demonstrated a high reduction of anal precancer-
ous lesions in the per protocol population (HPV negative 
subjects from 1 day to 7 month after the first vaccine 
administration receiving three doses of vaccine) with an 
efficacy up to 90% against anal intraepithelial neoplasia 
(AIN and AIN2+) lesions which are direct precursor of 
anal cancer [86].
A recent cohort study conducted on 202 MSM patients 
with a history of previously treated high-grade anal in-
traepithelial neoplasia (HGAIN) showed a significant 
HGAIN recurrence reduction among patients vaccinated 
with HPV quadrivalent vaccine. These data suggest the 
possible use of the vaccine as an effective post-treatment 
adjuvant form of therapy in MSM patients with previous 
diagnosis of HGAIN [87].
Discussion
The HPV infection in males are associated with a sig-
nificant epidemiologic burden causing disease ranging 
from non-malignant conditions to malignant disease 
such as anal, penile and head and neck cancers. HPV re-
lated disease in males also have an important economic 
impact, as demonstrated by a recent study conducted in 
Italy which shows that the economic burden attributable 
to HPV 6,11,16 and 18 related disease in males, amount 
to 38.8 % of the total direct costs of HPV related dis-
eases [88].
Based on epidemiological consideration and on data 
about HPV vaccine efficacy in male population, FDA 
and EMA approved the extension of HPV vaccination 
to boys and men.
Some mathematical models highlighted how the exten-
sion of HPV vaccination coverage to males could reflect 
positively in terms of herd immunity, although suggest 
that the predicted efficacy of the vaccine strategies de-
pends on the characteristics of the infection in males that 
remain unclear in some aspects [89].
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The herd immunity effects elicited by quadrivalent HPV 
vaccine between sexual partners has been demonstrated 
in a study conducted in Australia; in this analysis a de-
crease of genital wart diagnosed cases among heterosex-
ual men was observed after the introduction of the HPV 
vaccination program targeting women [90].
Certain economic models concludeed that vaccination 
of males could be cost effective only in presence of a 
low vaccination coverage rate among females [91, 92].
These models were supported by the consideration that 
reaching vaccination coverage up to 50% in women the 
herd immunity effect could protect heterosexual men, 
disregarding MSM populations in which HPV infection 
and associated diseases incidence were significantly 
higher.
The introduction of the vaccine in MSM could exert a 
more positive benefit in terms of reduction in the num-
ber of anal cancer cases that represent in this popula-
tion an important cause of health care assistance request 
with an incidence equivalent to that of cervical cancer in 
women and even higher in HIV infected MSM. 
On the other hand, vaccination of MSM, representing a 
small portion of the males population could be cost ef-
fective but not ethically justified.
Moreover, in many developed countries, it has been ob-
served an upward trend in the burden of HPV-related 
diseases, especially anal cancer and oropharyngeal squa-
mous cell carcinomas in all men regardless of sexual ori-
entation. In the light of these data, ethical considerations 
and reasons of social fairness would advise against the 
choice of protecting males only through herd immunity, 
effect achievable only after decades.
Nevertheless, the implementation of vaccination pro-
grams in males is complicated by the reduced knowl-
edge about several aspects of natural history of the dis-
ease with particular regard to the transmission dynamics 
between sexual partners, concordance data about which 
are often conflicting. Another point to clarify is the defi-
nition of the factors such as immunomodulation path-
ways and genetic background that could influence the 
different duration and clearance of the infection in males 
respect to females. Furthermore an important aspect to 
consider is the lack of a reference-screening test univer-
sally accepted for clinical diagnosis of HPV in males.
Several countries including the United States, Canada 
and Australia have introduced vaccination programs for 
boys and men since 2009. Currently, in United States 
CDC recommends HPV quadrivalent vaccine for all 
boys aged 11 or 12 years, and for males aged 13 through 
21 years, who did not get any or all of the three recom-
mended doses when they were younger. HPV quadriva-
lent vaccine is also recommended for gay and bisexual 
men and men with compromised immune systems (in-
cluding HIV) through age 26.
Given the clinical implications as well as the high eco-
nomic burden associated to HPV in males, implemen-
tation of HPV vaccination strategies dedicated to men 
requires depth assessment. 
References
[1] Lacey CJ. Therapy for genital human papillomavirus-related 
disease. J Clin Virol 2005;32(Suppl 1):S82-90.
[2] Walboomers JM, Jacobs MV, Manos MM, et al. Human pap-
illomavirus is a necessary cause of invasive cervical cancer 
worldwide. J Pathol 1999;189:12-9.
[3] Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavi-
rus and cervical cancer. Lancet 2007;370:890-907.
[4] Franco EL, Harper DM. Vaccination against human papillo-
mavirus infection: a new paradigm in cervical cancer control. 
Vaccine 2005;23:2388-94.
[5] Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-specific 
prevalence of anal human papillomavirus infection in HIV-
negative sexually active men who have sex with men: the EX-
PLORE study. J Infect Dis 2004;190:2070-6.
[6] Vajdic CM, van Leeuwen MT, Jin F, Prestage G, et al. Anal 
human papillomavirus genotype diversity and co-infection in a 
community-based sample of homosexual men. Sex Transm In-
fect 2009; 85:330–5.
[7] Agarwal SS, Sehgal A, Sardana S, et al. Role of male behav-
ior in cervical carcinogenesis among women with one lifetime 
sexual partner. Cancer 1993;72:1666-9.
[8] Castellsague X, Bosch FX, Munoz N, et al. Male circumcision, 
penile human papillomavirus infection, and cervical cancer in 
female partners. N Engl J Med 2002;346:1105-12.
[9] Watson M, Saraiya M, Ahmed F, et al. Using population-based 
cancer registry data to assess the burden of human papillo-
mavirus-associated cancers in the United States: overview of 
methods. Cancer 2008;113(10 Suppl):2841-54.
[10] IARC. Monographs on the evaluation of carcinogenic risk to 
humans. Vol.90. Human Papillomaviruses. Lyon: IARC 2007.
[11] FDA. Licensure of Quadrivalent Human Papillomavirus Vac-
cine (HPV4, Gardasil) for use in males and guidance from 
the Advisory Committee on Immunization Practices (ACIP). 
MMWR 2010;59:630-2 available at http://www.cdc.gov/
mmwr/preview/mmwrhtml/mm5920a5.htm.
[12] FDA. http.//www.fda.gov/newsevents/newsroom/pressannounce-
ments/ucm237941.htm.
[13] EMA. Assessment report. EMA/653012/2011 Committee for 
Medicinal Products for Human Use (CHMP). 23 June 2011.
[14] Siegel JF, Mellinger BC. Human papillomavirus in the male 
patient. Urol Clin North Am 1992;19:83-91.
[15] Baker CC, Phelps WC, Lindgren V, et al. Structural and tran-
scriptional analysis of human papillomavirus type 16 sequences 
in cervical carcinoma cell lines. J Virol 1987;61:962-71.
[16] Corden SA, Sant-Cassia LJ, Easton AJ, et al. The integration of 
HPV-18 DNA in cervical carcinoma. Mol Pathol 1999;52:275-82.
[17] Ramírez-Salazar E, Centeno F, Nieto K, et al. HPV16 E2 could 
act as down-regulator in cellular genes implicated in apoptosis, 
proliferation and cell differentiation. Virol J 2011;8:247.
[18] Münger K, Howley PM. Human papillomavirus immortaliza-
tion and transformation functions. Virus Res 2002;89:213-28.
[19] Muñoz N, Bosch FX, de Sanjosé S, et al. International Agency 
for Research on Cancer Multicenter Cervical Cancer Study 
Group. Epidemiologic classification of human papilloma-
virus types associated with cervical cancer. N Engl J Med 
2003;348:518-27.
[20] Goedert JJ, Coté TR, Virgo P, et al. Spectrum of AIDS-associat-
ed malignant disorders. Lancet 1998;351:1833-9.
[21] Giuliano AR, Nielson CM, Flores R, et al. The optimal ana-
tomic sites for sampling heterosexual men for human papillo-
mavirus (HPV) detection: the HPV detection in men study. J 
Infect Dis 2007;196:1146-52.
HPV related diseases in males: a HeaVy Vaccine-PreVentable burden
69
[22] Partridge JM, Hughes JP, Feng Q, et al. Genital human papillo-
mavirus infection in men: incidence and risk factors in a cohort 
of university students. J Infect Dis 2007;196:1128-36.
[23] Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of 
genital human papillomavirus infection in men (HIM): a cohort 
study. Lancet 2011;377:932-40.
[24] Akogbe GO, Ajidahun A, Sirak B, et al. Race and prevalence of 
human papillomavirus infection among men residing in Brazil, 
Mexico and the United States. Int J Cancer 2012;131:E282-91.
[25] Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, 
incidence, and duration of human papillomavirus infections in 
a cohort of 290 US men. J Infect Dis 2008;198:827-35.
[26] Burchell AN, Tellier PP, Hanley J, et al. Human papillomavirus 
infections among couples in new sexual relationships. Epidemi-
ology 2010;21:31-7.
[27] Burchell AN, Coutlée F, Tellier PP, et al. Genital transmission 
of human papillomavirus in recently formed heterosexual cou-
ples. J Infect Dis 2011;204:1723-9.
[28] Nyitray AG, Menezes L, Lu B, et al. Genital human papilloma-
virus (HPV) concordance in heterosexual couples. J Infect Dis 
2012;206:202-11.
[29] Bosch FX, Castellsagué X, Muñoz N, et al. Male sexual behav-
ior and human papillomavirus DNA: key risk factors for cervi-
cal cancer in Spain. J Natl Cancer Inst 1996;88:1060-7.
[30] Guzmán-Esquivel J, Martínez-Contreras A, Ramírez-Flores M, 
et al. Association between human papillomavirus in men and 
their sexual partners and uterine cervical intraepithelial neo-
plasia. Int Urol Nephrol 2009;41:335-40.
[31] Martín-Ezquerra G, Fuste P, Larrazabal F, et al. Incidence of hu-
man papillomavirus infection in male sexual partners of women 
diagnosed with CIN II-III. Eur J Dermatol 2012;22:200-4.
[32] CDC. Sexually transmitted diseases treatment guidelines. 
MMWR 2006;vol.55;RR-11:1-94.
[33] Gavillon N, Vervaet H, Derniaux E, et al. How did I con-
tract human Papillomavirus (HPV)? Gynecol Obstet Fertil 
2010;38:199-204.
[34] Insinga RP, Dasbach EJ, Myers ER. The health and economic 
burden of genital warts in a set of private health plans in the 
United States. Clin Infect Dis 2003;36:1397-403. 
[35] Langley PC, White DJ, Drake SM. The costs of treating exter-
nal genital warts in England and Wales: a treatment pattern 
analysis. Int J STD AIDS 2004;15:501-8.
[36] Jeynes C, Chung MC, Challenor R. ‘Shame on you’ - the psycho-
social impact of genital warts. Int J STD AIDS 2009;20:557-60.
[37] Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and man-
agement of non-cancerous HPV-related conditions:HPV-6/11 
disease. Vaccine 2006;24(Suppl.3):S35e41.
[38] Garland SM, Steben M, Sings HL, et al. Natural history of geni-
tal warts: analysis of the placebo arm of 2randomized phase III 
trials of a quadrivalent human papillomavirus (types 6, 11, 16, 
and 18) vaccine. J Infect Dis 2009;199:805e14.
[39] Winer RL, Kiviat NB, Hughes JP, et al. Development and dura-
tion of human papillomavirus lesions, after initial infection. J 
Infect Dis 2005;191:731e8.
[40] Giuliano A, Palefsky J. The efficacy of quadrivalent HPV (types 
6/11/16/18) vaccine in reducing the incidence of HPV-related 
genital disease in young men. 2008 Conference of the European 
Research Organization on Genital Infection and Neoplasia 
(EUROGIN); 2008; Nice, France. Abstract SS 19-7a.
[41] Chan PK, Luk AC, Luk TN, et al. Distribution of human pap-
illomavirus types in anogenital warts of men. J Clin Virol 
2009;44:111-4.
[42] Brown DR, Schroeder JM, Bryan JT, et al. Detection of multiple 
human papillomavirus types in condylomata acuminata lesions 
from otherwise healthy and immunosuppressed patients. J Clin 
Microbiol 1999;37:3316-22.
[43] CDC. http://www.cdc.gov/std/hpv/STDFact-HPV-and-men.htm 
[44] Kraut AA, Schink T, Schulze-Rath R et al. Incidence of ano-
genital warts in Germany: a population-based cohort study. 
BMC Infect Dis 2010;10:360.
[45] Desai S, Wetten S, Woodhall SC et al. Genital warts and cost of 
care in England. Sex Transm Infect 2011;87:464-8.
[46] Hartwig S, Syrjänen S, Dominiak-Felden G, et al. Estimation 
of the epidemiological burden of human papillomavirus-related 
cancers and non-malignant diseases in men in Europe: a re-
view. BMC Cancer 2012;12:30. 
[47] HPA. http://www.hpa.org.uk/
[48] Leval A, Herweijer E, Arnheim-Dahlström L, et al. Incidence 
of genital warts in Sweden before and after quadrivalent human 
papillomavirus vaccine availability. J Infect Dis 2012;206:860-6.
[49] Suligoi B, Salfa MC, Mariani L. Epidemiology and manage-
ment of patients with ano-genital warts in Italy. Ig Sanita Pubbl 
2010;66:733-56.
[50] Majewski S, Jablonska S. Human papillomavirus-associ-
ated tumors of the skin and mucosa. J Am Acad Dermatol 
1997;36:659-85.
[51] Derkay CS. Task force on recurrent respiratory papillomas. 
A preliminary report. Arch Otolaryngol Head Neck Surg 
1995;121:1386-91.
[52] Kashima HK, Shah F, Lyles A, et al. A comparison of risk fac-
tors in juvenile-onset and adult-onsetrecurrent respiratory pap-
illomatosis. Laryngoscope 1992;102:9-13.
[53] Human papilloma virus and related cancers Summary Report 
Update. September 15, 2010.WHO ICO, Third edition, 2010.
[54] Varnai AD, Bollmann M, Griefingholt H, et al. HPV in anal 
squamous cell carcinoma and anal intraepithelial neoplasia 
(AIN). Impact of HPV analysis of anal lesions on diagnosis and 
prognosis. Int J Colorectal Dis 2006;21:135-42.
[55] Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-asso-
ciated cancers in patients with human immunodeficiency virus 
infection and acquired immunodeficiency syndrome. J Natl 
Cancer Inst 2000;92:1500-10.
[56] Piketty C, Selinger-Leneman H, Grabar S, et al. FHDH-ANRS 
CO 4. Marked increase in the incidence of invasive anal cancer 
among HIV-infected patients despite treatment with combina-
tion antiretroviral therapy. AIDS 2008;22:1203-11.
[57] Crum-Cianflone NF, Hullsiek KH, Marconi VC, et al. Infec-
tious Disease Clinical Research Program HIV Working Group. 
Anal cancers among HIV-infected persons: HAART is not slow-
ing rising incidence. AIDS 2010;24:535-43.
[58] Piketty C, Selinger-Leneman H, Bouvier AM, et al. Incidence 
of HIV-Related Anal Cancer Remains Increased Despite Long-
Term Combined Antiretroviral Treatment: Results From the 
French Hospital Database on HIV. J Clin Oncol 2012;30:4360-6.
[59] Partridge JM, Koutsky LA. Genital human papillomavirus in-
fection in men. Lancet Infect Dis 2006;6:21-31.
[60] Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexu-
ally transmitted diseases, and the incidence of anal cancer. N 
Engl J Med 1987;317:973-7.
[61] Nyitray A, Nielson CM, Harris RB, et al. Prevalence of and risk 
factors for anal human papillomavirus infection in heterosexual 
men. J Infect Dis 2008;197:1676-84.
[62] Nyitray AG, Carvalho da Silva RJ, Baggio ML et al. Age-spe-
cific prevalence of and risk factors for anal human papillomavi-
rus (HPV) among men who have sex with women and men who 
have sex with men: the HPV in men (HIM) study. J Infect Dis 
2011;203:49-57.
[63] Stanley MA, Winder DM, Sterling JC, et al. HPV infection, 
anal intra-epithelial neoplasia (AIN) and anal cancer: current 
issues. BMC Cancer 2012;12:398. 
[64] Nyitray AG, Carvalho da Silva RJ, Baggio Ml et al. Six-month 
incidence, persistence, and factors associated with persistence 
of analhuman papillomavirus in men: the HPV in men study. J 
Infect Dis 2011;204:1711-22.
P. CanePa et al.
70
[65] Parkin DM. The global health burden of infection-associated 
cancers in the year 2002. Int J Cancer 2006;118:3030-44.
[66] http://www.cdc.gov/cancer/hpv/statistics/penile.htmCDC
[67] AIRTUM ITACAN: Tumori in Italia, Versione 1. Associazione 
Italiana dei Registri Tumori http://www.registri-tumori.it.
[68] IARC. Monographs on the evaluation of carcinogenic risks to 
humans.Vol.90.Human Papillomaviruses. IARC Lyon 2005
[69] Rubin MA, Kleter B, Zhou M, et al. Detection and typing of 
human papillomavirus DNA in penile carcinoma: evidence for 
multiple independent pathways of penile carcinogenesis. Am J 
Pathol 2001;159:1211-8.
[70] Bezerra AL, Lopes A, Landman G, et al. Clinicopathologic 
features and human papillomavirus dna prevalence of warty 
and squamous cell carcinoma of the penis. Am J Surg Pathol 
2001;25:673-8.
[71] Madsen BS, van den Brule AJ, Jensen HL, et al. Risk factors for 
squamous cell carcinoma of the penis—population-based case-
control study in Denmark. Cancer Epidemiol Biomarkers Prev 
2008;17:2683-91.
[72] Daling JR, Madeleine MM, Johnson LG, et al. Penile cancer: 
importance of circumcision, human papillomavirus and smoking 
in in situ and invasive disease. Int J Cancer 2005;116:606-16.
[73] Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in 
Five Continents, Vol. VIII. IARC Scientific Publications 2002; 
No. 155, Lyon, IARC.
[74] CDC http://www.cdc.gov/cancer/hpv/statistics/headneck.htm
[75] Herrero R, Castellsagué X, Pawlita M, et al. IARC Multicenter 
Oral Cancer Study Group. Human papillomavirus and oral 
cancer: the International Agency for Research on Cancer mul-
ticenter study. J Natl Cancer Inst 2003;95:1772-83.
[76] Smith EM, Ritchie JM, Summersgill KF, et al. Age, sexual be-
havior and human papillomavirus infection in oral cavity and 
oropharyngeal cancers. Int J Cancer 2004;108:766-72.
[77] Kreimer AR, Clifford GM, Boyle P, et al. Human papilloma-
virus types in head and neck squamous cell carcinomas world-
wide: a systematic review. Cancer Epidemiol Biomarkers Prev 
2005;14:467-75.
[78] D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study 
of human papillomavirus and oropharyngeal cancer. N Engl J 
Med 2007;356:1944-56.
[79] Foresta C, Garolla A, Zuccarello D, et al. Human papillomavi-
rus found in sperm head of young adult males affects the pro-
gressive motility. Fertil Steril 2010;93:802-6.
[80] Foresta C, Pizzol D, Moretti A, et al. Clinical and prognostic 
significance of human papillomavirus DNA in the sperm or ex-
foliated cells of infertile patients and subjects with risk factors. 
Fertil Steril 2010;94:1723-7.
[81] Foresta C, Patassini C, Bertoldo A, et al. Mechanism of human 
papillomavirus binding to human spermatozoa and fertilizing 
ability of infected spermatozoa. PloS One 2011;6:e15036.
[82] Perino A, Giovannelli L, Schillaci R, et al. Human papillo-
mavirus infection in couples undergoing in vitro fertilization 
procedures: impact on reproductive outcomes. Fertil Steril 
2011;95:1845-8.
[83] RCP Cervarix EMA.
[84] RCP Gardasil EMA.
[85] Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quad-
rivalent HPV vaccine against HPV Infection and disease in 
males. N Engl Jmed 2011;364:401-11.
[86] Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine 
against anal HPV infection and analintraepithelial neoplasia. 
N Engl J Med 2011;365:1576-85.
[87] Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent 
high-grade anal neoplasia with quadrivalent human papilloma-
virus vaccination of men who have sex with men: a nonconcur-
rent cohort study. Clin Infect Dis 2012;54:891-8.
[88] Baio G, Capone A, Marcellusi A, et al. Economic burden of 
humanpapillomavirus-related diseases in Italy. PloS One 
2012;7:e49699.
[89] Hughes JP, Garnett GP, Koutsky L. The theoretical population-
level impact of aprophylactic human papilloma virus vaccine. 
Epidemiology 2002;13:631-9.
[90] Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in pres-
entations of genital warts after the implementation of a national 
quadrivalent human papillomavirus vaccination programme 
for young women. Sex Transm Infect 2009;85:499-502.
[91] Garnett GP. Role of herd immunity in determining the effect 
of vaccines against sexually transmitted disease. J Infect Dis 
2005;191(Suppl. 1):S97-106. 
[92] Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effec-
tiveness of male HPV vaccination in the United States. Vaccine 
2011;29:8443-50.
n	 List of abbreviations and acronyms:
 HPV, human papillomavirus
 MSM, Man having sex with Man
 IARC, International Agency for Research on Cancer
 FDA, Food and Drug Administration
 CHMP, Committee for Medicine Products for Human Use
 EMA, European Medicines Agency
 ORFs, open reading frames
 HIV, Human immunodeficiency virus
 URR, upstream regulatory region
 LCR, long control region
 HIM, HPV in Men
 CIN, cervical intraepithelial neoplasia
 CDCs, Centers for Disease Control and Prevention
 GUM, Genitourinary Medicine
 STIs, sexually transmitted infections
 STDs, sexually transmitted diseases
 RRP, Recurrent Respiratory Papillomatosis
 SCC, squamous cell carcinoma
 AIN, anal intraepithelial neoplasia
 HAART, Highly Active Antiretroviral Therapy
 cART, combined antiretroviral treatment
 SIRs, Standardized incidence ratios
 HNSCCs, Head and neck squamous cell carcinomas
 ARTs, assisted reproductive technologies
 HGAIN, high-grade anal intraepithelial neoplasia
n	 Received on January 10, 2013. Accepted on February 2, 2013.
n	 Correspondence: P. Canepa, Department of Health Sciences, Uni-
versity of Genoa, via Pastore 1, 16132 Genoa, Italy - E-mail: pao-
la.canepa@unige.it
